Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers

5 September 2023

Telix is looking forward to our next symposium at the Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria. We have an exciting line-up of expert speakers who will each present on important developments in the personalisation of diagnostics in urological cancers before opening the discussion up to the floor. Nuclear medicine is a fast-moving field, so don’t miss out on the opportunity to enhance your knowledge and discover new viewpoints in oncology.

City
Vienna, Austria

Time
Sunday 10th September 2023 from 13:15 – 14:45 (CEST)

Location
Hall F1 – Austria Center Vienna

  • Prof. Stefano Fanti (Chair), Director of Nuclear Medicine, Division and of PET Unit – Policlinico S.Orsola, Bologna, Italy
    Introduction: How PSMA-PET dusted off the Management of Prostate Cancer
  • Dr. Macarena Rodríguez Fraile, Nuclear Medicine Clínica Universidad de Navarra, Pamplona, Spain
    Prostate Cancer Imaging: is there only one PSMA-PET?
  • Prof. dr. Karolien Goffin, Nuclear Medicine, University Hospital Leuven – KU Leuven, Leuven, Belgium
    Next Generation Imaging in Urology: what’s new in Bladder and Kidney Cancers
  • Dr. László Papp, Center for Medical Physics and Biomedical Engineering (CMPBME), Medical University of Vienna, Vienna, Austria
    The Use of Artificial Intelligence in Prostate Cancer Management

Speaker biographies


Prof. Stefano Fanti (Chair and Speaker)

Prof. Fanti has been Associate Professor at the University of Bologna since 2006 and Full Professor since 2017. His research is focused on the field of diagnostics, particularly in Nuclear Medicine and the use of PET in oncology, with particular reference to innovative radiopharmaceuticals. Prof. Fanti is engaged in national and international research projects, collaborating with numerous institutions, including IAEA and EANM. He has authored numerous publications in his field and has received several awards and recognitions from prestigious Centers and Institutes.

Prof. Macarena Rodríguez Fraile (Speaker)

Macarena Rodríguez-Fraile is a Senior Consultant in Nuclear Medicine at Clínica Universidad de Navarra, Pamplona, Spain. She defended her PhD in 2011 with the thesis entitled “Diagnostic and prognostic value of PET/CT with 18F-FDG and 11C-Choline in prostate carcinoma”. Her main areas of research are imaging in prostate cancer, in breast cancer, liver radioembolization and bone densitometry. She is a professor at the Faculty of Medicine of Universidad de Navarra. She is currently the president of the Oncology Group of the Spanish Society of Nuclear Medicine.

Prof. Karolien Goffin (Speaker)

Prof. Dr. Karolien Goffin is a staff member of nuclear medicine at the University Hospital Leuven and associate professor at KU Leuven, Leuven, Belgium. She is part of the multidisciplinary teams dealing with uro-oncology, among others. Her main research interests are preclinical development of diagnostic and therapeutic radiopharmaceuticals, the application of existing oncological PET tracers in a broad range of malignancies and clinical settings and the introduction of novel PET tracers and therapeutic radiopharmaceuticals in (uro-)oncology. Prof. Goffin is chair of the Oncology and Theranostics Committee of EANM, board member of the Belgian Multidisciplinary meeting on Urological Cancers (BMUC) and member of the Imaging Group of the European Organization for Research and Treatment of Cancer (EORTC). She is associate editor of EJNMMI and editorial board member of JNM, Cancers and Clinical and Translational Imaging.

Dr. László Papp (Speaker)

László Papp obtained his medical physics PhD at the Medical University of Vienna (MUV) in 2021, focusing on medical image analysis with artificial intelligence (AI) approaches. He is the co-fouder of Dedicaid GmbH, a spin-off of MUV, which was acquired and now wholly-owned by Telix Pharmaceuticals. Within Dedicaid, he conceptualized and implemented the AI solutions to aid the building process of cloud AI clinical decision support systems (CDSS). Before becoming a researcher at MUV, he was the head of software R&D operations at a major medical imaging company in Hungary for almost 10-years. He is currently a full-time postdoc at MUV, building his research team as the group lead of the Applied Quantum Computing (AQC) group.

What a line up – we can’t wait for you to join us in Vienna!